Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis

Giuseppe Fallara(Istituti di Ricovero e Cura a Carattere Scientifico), Alberto Martini(The University of Texas MD Anderson Cancer Center), Bernard Malavaud(Institut universitaire du cancer de Toulouse Oncopole), Daniele Robesti(Vita-Salute San Raffaele University), Luigi Nocera(Istituti di Ricovero e Cura a Carattere Scientifico), Daniele Raggi(Fondazione IRCCS Istituto Nazionale dei Tumori), Francesco Montorsi(Vita-Salute San Raffaele University), Andrea Necchi(Vita-Salute San Raffaele University), Laura Marandino, Guillaume Ploussard(Yves Rocher (France)), Federico Belladelli(IRCCS Ospedale San Raffaele)
Cancer Treatment Reviews
July 26, 2022
10.1016/j.ctrv.2022.102441
Cited by 33

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|656